To read the full story, subscribe or sign in.

Failed Phase III Dims Picoplatin's SCLC Chances, Partnering Plans

Nov. 17, 2009

Shares of Poniard Pharmaceuticals Inc. tumbled 76 percent on disappointing data from its Phase III trial of picoplatin in small-cell lung cancer, news that's certain to hamper ongoing discussions for a much-needed partnership. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for May 7, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 5, 2026

The epidermal growth factor receptor in the inactive (left) and active (right) form.

Cytospire raises £61M series A to target EGFR in solid tumors

BioWorld

Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...

Bio Korea 2026: US policy risks shift to execution framework

BioWorld

Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...

Regulatory actions for May 5, 2026

BioWorld

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...